Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride

Journal of the American Geriatrics Society

Volumn 46, Issue 1, 1998, Pages 8-13

  Katz, Ira R ^a   Sands, Laura Prouty ^b   Bilker, Warren ^a   DiFilippo, Suzanne ^a   Boyce, Alice ^a   D'Angelo, Kristina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; OXYBUTYNIN; PLACEBO; SPASMOLYTIC AGENT;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0031963397     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb01006.x     Document Type: Article

References (28)

1. Morrison RL, Katz IR. Drug-related cognitive impairment: Current progress and recurrent problems. Annu Rev Geriatr Gerontol 1989;9:232-284.
2. General Accounting Office. Prescription drugs and the elderly - Many still receive potentially harmful drugs despite recent improvements. Report No. GAO/HEHS-95-152. Washington, DC: General Accounting Office, 1995.
3. Lipowski ZB. Delirium. Acute confusional states. New York: Oxford University Press, 1990.
4. Larson EB, Kukall WA, Buchner D et al. Adverse drug reactions associated with global cognitive impairment in the elderly. Ann Intern Med 1987;107:169-173.
5. Physicians' Desk Reference, 49th Ed. Montvale, NJ: Medical Economics Data Production Company, 1995, pp 1407-1408.
6. Pietzko A, Dimpfel W, Schwantes U et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994;47:337-343.
7. Banerjee S, Routledge PA, Pugh S et al. Poisoning with oxybutynin. Hum Exp Toxicol 1991;10:225-226.
8. Choulot JJ, Mensire A, Saint Martin J. Surdosage en atropiniques et syndrome confusionnel. Ann Pediatr 1989;36:714.
9. Thuroff JW, Bunke B, Ebner A et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo. J Urol 1991;145:813-816.
10. Moore KH, Hay DM, Imrie AE et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 1990;66:479-485.
11. Zorzitto ML, Holliday PJ, Jewett MA et al. Oxybutynin chloride for geriatric urinary dysfunction: A double-blind placebo-controlled study. Age Ageing 1989;18:195-200.
12. Baigrie RJ, Kelleher JP, Fawcett DP et al. Oxybutynin: Is it safe? Br J Urol 1988;62:319-322.
13. Kirkali Z, Whitaker RH. The use of oxybutynin in urological practice. Int Urol Nephrol 1987;19:385-391.
14. Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol 1984;11:37-42.
15. Ouslander JG, Blaustein J, Connor A et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988;140:47-50.
16. Sands LP, Katz IR, Doyle S. Detecting subclinical change in cognitive functioning in older adults. Part I: Explication of the method. Am J Geriatr Psychiatry 1993;1:185-196.
17. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
18. Folstein MF, Folstein SE, McHug PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1983;17:37-49.
20. Berlinger WG, Goldberg MJ, Spector R et al. Diphenhydramine: Kinetics and psychomotor effects in elderly women. Clin Pharmacol Ther 1982;32:387-391.
21. Gengo F, Gabos C, Miller JK. The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental performance. Clin Pharmacol Ther 1989;45:15-21.
22. Simmons KJ, Watson WT, Martin TJ et al. Diphenhydramine pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol 1990;30:665-671.
23. Douchamps J, Derenne F, Stockis A et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988;35:515-520.
24. Aaltonen L, Allonen H, Iisalo E et al. Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol Toxicol 1984;55:100-103.
25. Hughes KM, Lang JC, Lazare R et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-869.
26. Letz R, Baker L. NES 2-Neurobehavioral Evaluation System. New York: Neurobehavioral Systems, Inc. 1988.
27. Gibbons RD, Hedeker D, Waternaux C et al. Random regression models: A comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmcol Bull 1988;24:438-443.
28. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res 1988;472:371-389.